# Acceleron Pharma, Inc., a wholly-owned trials: 26 (2026)

ClinicalTrials.gov lists 26 trials with Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA: 26 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-and-co-inc-rah

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 2, 2021 | NCT04948554 | A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 1 | Terminated | Systemic Sclerosis With and Without Interstitial Lung Disease | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04948554) |
| June 30, 2021 | NCT04945460 | A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Completed | Hypertension, Pulmonary | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04945460) |
| May 21, 2021 | NCT04896008 | A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 3 | Completed | Pulmonary Arterial Hypertension | 173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04896008) |
| March 23, 2021 | NCT04811092 | Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 3 | Terminated | Pulmonary Arterial Hypertension | 321 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04811092) |
| October 6, 2020 | NCT04576988 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 3 | Completed | Pulmonary Arterial Hypertension | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04576988) |
| May 9, 2019 | NCT03943290 | Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and... | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Terminated | Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03943290) |
| November 13, 2018 | NCT03738150 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Completed | Pulmonary Arterial Hypertension | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03738150) |
| April 12, 2018 | NCT03496207 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Completed | Pulmonary Arterial Hypertension | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03496207) |
| March 27, 2018 | NCT03478319 | A Study of ACE-2494 in Healthy Subjects | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 1 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03478319) |
| April 21, 2017 | NCT03124459 | Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Terminated | Charcot-Marie-Tooth Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03124459) |
| October 6, 2016 | NCT02927080 | Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Terminated | Facioscapulohumeral Muscular Dystrophy | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02927080) |
| October 20, 2014 | NCT02268409 | Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04... | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Completed | β-Thalassemia | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02268409) |
| October 20, 2014 | NCT02268383 | Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Completed | Myelodysplastic Syndromes | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02268383) |
| October 6, 2014 | NCT02257489 | Phase 1 Study of ACE-083 in Healthy Subjects | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 1 | Completed | Musculoskeletal Diseases | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02257489) |
| December 31, 2013 | NCT02024087 | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 1/2 | Completed | Advanced Adult Hepatocellular Carcinoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02024087) |
| December 13, 2012 | NCT01749540 | Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Completed | B-Thalassemia | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01749540) |
| December 13, 2012 | NCT01749514 | Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Completed | Anemia | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01749514) |
| November 16, 2012 | NCT01727336 | Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Terminated | Advanced Renal Cell Carcinoma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01727336) |
| October 24, 2011 | NCT01458392 | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Completed | Squamous Cell Carcinoma of the Head and Neck | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01458392) |
| September 13, 2011 | NCT01432717 | Study of ACE-536 in Healthy Postmenopausal Women | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 1 | Completed | Anemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01432717) |
| November 11, 2010 | NCT01239758 | Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Terminated | Duchenne Muscular Dystrophy | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01239758) |
| April 8, 2010 | NCT01099761 | Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 | Terminated | Duchenne Muscular Dystrophy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01099761) |
| October 16, 2009 | NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 1 | Completed | Advanced Solid Tumors, Multiple Myeloma | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00996957) |
| August 6, 2009 | NCT00952887 | A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 1 | Completed | Muscular Atrophy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00952887) |
| September 19, 2008 | NCT00755638 | A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 1 | Completed | Muscle Loss | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00755638) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 1 |
| Phase 2 | 14 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 18 |
| Terminated | 8 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pulmonary Arterial Hypertension | 5 |
| Hypertension | 3 |
| Anemia | 2 |
| Muscular Dystrophy, Facioscapulohumeral | 2 |
| Myelodysplastic Syndromes | 2 |
| Muscular Atrophy | 2 |
| Charcot-Marie-Tooth Disease | 2 |
| Hypertension, Pulmonary | 2 |
| Muscular Dystrophy, Duchenne | 2 |
| Musculoskeletal Diseases | 1 |
| Multiple Myeloma | 1 |
| Charcot-Marie-Tooth disease, X-linked, 1 | 1 |
| beta-Thalassemia | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Osteoporosis | 1 |
| Scleroderma, Diffuse | 1 |
| Scleroderma, Systemic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Nursing schools in the United States](https://specstream.ai/data/businesses/nursing-schools/united-states)
- [Driving schools in the United States](https://specstream.ai/data/businesses/driving-schools/united-states)
- [Vending machine suppliers in the United States](https://specstream.ai/data/businesses/vending-machine-suppliers/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Cuban restaurants in the United States](https://specstream.ai/data/businesses/cuban-restaurants/united-states)
- [Traffic ticketing law firms in the United States](https://specstream.ai/data/businesses/traffic-ticketing-law-firms/united-states)
